CLAZF OTC
Claritas Pharmaceuticals, Inc.
1W: -99.0%
1M: -99.0%
3M: -99.0%
YTD: -99.0%
1Y: -99.0%
3Y: -99.8%
5Y: -100.0%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$3M
+65.3% ▲
Net Income
$4M
+119.8% ▲
EPS (Diluted)
$0.16
+116.0% ▲
EBITDA
-$3M
+70.6% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $19K | $0 | $0 | $0 | $0 |
| Gross Profit | -$19K | $0 | $0 | $0 | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $2M | $2M | $8M | $6M | -$2M |
| SG&A Expenses | $3M | $3M | $3M | $4M | $2M |
| Operating Expenses | $5M | $5M | $11M | $9M | -$184K |
| Operating Income | -$12M | -$14M | -$11M | -$9M | -$3M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $0 | $16M | $153K | $209K | $225K |
| Income Before Tax | -$12M | -$32M | $7M | -$26M | -$674K |
| Tax Expense | $107 | -$2M | -$99K | -$5M | -$5M |
| Net Income | -$12M | -$32M | $7M | -$21M | $4M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-7.80 | $-5.20 | $0.64 | $-1.00 | $0.16 |
| EBITDA | -$11M | -$15M | $18M | -$17M | -$3M |
| Shares Outstanding | 1M | 6M | 11M | 22M | 27M |